SCHEMBL7185783

SCHEMBL7185783

N#Cc1cnc(Nc2ccc3[nH]ccc3c2)c(N)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 8/20 0.53
▸ FGFR2 P21802 1/20 0.50
▸ FLT3 P36888 1/20 0.50
▸ IMPDH2 P12268 1/20 0.48
▸ IMPDH1 P20839 1/20 0.48
▸ FLT1 P17948 5/20 0.47
▸ PRKCQ Q04759 3/20 0.44
▸ PRKCD Q05655 3/20 0.44
▸ LYN P07948 1/20 0.44
▸ KDR P35968 3/20 0.43
▸ SYK P43405 2/20 0.42
▸ PIK3CA P42336 1/20 0.42
▸ PIK3CG P48736 1/20 0.42
▸ PRKCH P24723 1/20 0.41
▸ PRKCE Q02156 1/20 0.41
▸ GABRP O00591 1/20 0.41
▸ GABRD O14764 1/20 0.41
▸ GABRA1 P14867 1/20 0.41
▸ GABRB1 P18505 1/20 0.41
▸ GABRG2 P18507 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7187168 0.81 EGFR (0.49) EGFRFGFR2FLT3IMPDH2IMPDH1
SCHEMBL2543646 0.81 ADRA2A (0.41) EGFR
SCHEMBL7369210 0.79 IMPDH2 (0.59) EGFRFGFR2FLT3IMPDH2IMPDH1
SCHEMBL2543648 0.78 ADRA2A (0.53) SYKPIK3CA
SCHEMBL5527077 0.75 PRKCQ (0.51) EGFRFGFR2FLT3IMPDH2IMPDH1
SCHEMBL1643102 0.74 FGFR2 (0.57) EGFRFGFR2FLT3FLT1KDR
SCHEMBL2975972 0.73 GRM4 (0.54) EGFRFGFR2FLT3IMPDH2IMPDH1
SCHEMBL7547492 0.73 IMPDH2 (0.48) EGFRIMPDH2IMPDH1PRKCQGABRP
SCHEMBL27252329 0.73 TNF (0.40) SYKPIK3CA
SCHEMBL1641747 0.72 FGFR2 (0.67) EGFRFGFR2FLT3FLT1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 — — US disclosed
Send feedback